Literature DB >> 7959217

New salicylates as maintenance treatment in ulcerative colitis.

G Järnerot1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7959217      PMCID： PMC1375685          DOI： 10.1136/gut.35.9.1155

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  30 in total

1.  Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis.

Authors:  C J Mulder; G N Tytgat; I T Weterman; W Dekker; P Blok; M Schrijver; H van der Heide
Journal:  Gastroenterology       Date:  1988-12       Impact factor: 22.682

2.  Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group.

Authors:  P Rutgeerts
Journal:  Aliment Pharmacol Ther       Date:  1989-04       Impact factor: 8.171

3.  Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas.

Authors:  M Campieri; G A Lanfranchi; G Bazzocchi; C Brignola; F Sarti; G Franzin; A Battocchia; G Labo; P R Dal Monte
Journal:  Lancet       Date:  1981-08-08       Impact factor: 79.321

4.  Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.

Authors:  L Staerk Laursen; M Stokholm; K Bukhave; J Rask-Madsen; K Lauritsen
Journal:  Gut       Date:  1990-11       Impact factor: 23.059

5.  Nephrotoxic lesions from 5-aminosalicylic Acid.

Authors:  I C Calder; C C Funder; C R Green; K N Ham; J D Tange
Journal:  Br Med J       Date:  1972-01-15

6.  Sulphasalazine induced renal failure.

Authors:  A D Dwarakanath; J Michael; R N Allan
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

7.  Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day.

Authors:  M H Giaffer; C D Holdsworth; J E Lennard-Jones; C A Rodrigues; P B McIntyre; S Manjunatha; J H Baron; I G Barrison; R J Polson; A M Hoare
Journal:  Aliment Pharmacol Ther       Date:  1992-08       Impact factor: 8.171

8.  5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans.

Authors:  S N Rasmussen; S Bondesen; E F Hvidberg; S H Hansen; V Binder; S Halskov; H Flachs
Journal:  Gastroenterology       Date:  1982-11       Impact factor: 22.682

9.  Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis.

Authors:  L R Sutherland; G R May; E A Shaffer
Journal:  Ann Intern Med       Date:  1993-04-01       Impact factor: 25.391

10.  Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide.

Authors:  R P Chan; D J Pope; A P Gilbert; P J Sacra; J H Baron; J E Lennard-Jones
Journal:  Dig Dis Sci       Date:  1983-07       Impact factor: 3.199
View more
  4 in total

Review 1.  Advanced and controlled drug delivery systems in clinical disease management.

Authors:  J R Brouwers
Journal:  Pharm World Sci       Date:  1996-10

Review 2.  Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 3.  Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.

Authors:  A Prakash; A Markham
Journal:  Drugs       Date:  1999-03       Impact factor: 11.431

Review 4.  Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease.

Authors:  C J Mulder; S J van den Hazel
Journal:  Mediators Inflamm       Date:  1998       Impact factor: 4.711
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.